The Cell & Gene therapy investor day provides institutional, strategic and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools. The event includes clinical and commercial experts on-hand to address specific questions regarding the outlook for these products, and how this sector is impacting key therapeutic areas including oncology, ophthalmology, rare disease, diabetes, cardiovascular disease, wound healing and tissue repair and neurodegenerative diseases. The program includes talks by key opinion leaders in the industry, analysts closely following the sector as well as presentations by more than 30 leading companies from across the globe.
David Venables, CEO of Synpromics, will be presenting.
To register your interest click here.